Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cepheid Flu Test Wins First CLIA Waiver For PCR Panel

This article was originally published in The Gray Sheet

Executive Summary

FDA granted both a 510(k) clearance and a waiver for point-of-care use to Cepheid’s Xpert Flu +RSV Express test – the first molecular-based, polymerase chain-reaction panel diagnostic to win a CLIA waiver.

You may also be interested in...

CLIA Waiver Granted To Roche For Quick Flu Test

Roche Diagnostics was recently granted a CLIA waiver allowing use of its Cobas Liat System molecular diagnostic to detect over 30 strains of Influenza A/B in doctors' offices and clinics.

Alere Flu Test Wins First CLIA Waiver For Nucleic Acid Assay

Alere’s i Influenza A & B test was granted a CLIA waiver Jan. 6, a step toward moving traditionally complex molecular diagnostics to a wider array of testing settings.

CLIA Waiver Wave? Applications Up In FY 2014 After A Prior-Year Lull

The volume of applications for diagnostic test waivers under the Clinical Laboratory Improvement Amendments increased fivefold in FY 2014, but the total numbers are small, and the change may simply reflect routine year-to-year variation.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts